Skip to main content

Table 3 Treatment and toxicity

From: Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes

  All patients (n = 282) Patients without visceral metastasis (n = 220) Patients with visceral metastasis (n = 62)
   Curative treatment (n = 151) BSC
(n = 69)
Palliative treatment (n = 30) BSC
(n = 32)
Dysphagia palliative treatment      
naso-gastric tubes 15 (5.3%) 7 (4.6%) 4 (5.8%) * 3 (10.0%) 1 (3.1%) **
gastrostomy 11 (3.9%) 4 (2.6%) 6 (8.7%) 0 1 (3.1%)
endoscopic dilation 44 (15.6%) 19 (12.6%) 14 (20.3%) 5 (16.7%) 5 (3.1%)
oesophageal stent 63 (22.3%) 3 (2.0%) 37 (53.6%) 5 (16.7%) 18 (3.1%)
Initial cancer treatment      
Mucosectomy 6 (2.1%) 6 (4.0%) - - -
PDT 18 (6.4%) 14 (9.3%) 3 (4.3%) 1 (3.3%) -
Surgery 13 (4.6%) 13 (8.6%) - - -
Chemoradiotherapy 119 (42.2%) 111 (73.5%) - - -
Radiotherapy 8 (2.8%) 7 (4.6%) - - -
Chemotherapy 22 (7.8%) - 2 (2.9%) 20 (66.7%) -
Severe adverse effects 48 (17.0%) 31 (20.5%) 4 (5.8%) * 10 (33.3%) 3 (9.4%) **
Dysphagia evolution      
Regression at 2 months (n = 229) 139 (60.7%) 87 (64.0%) 25 (52.12%) 16 (55.2%) 11 (68.7%)
Recurrence (n = 103) 60 (58.2%) 35 (67.3%) 15 (68.2%) 7 (36.8%) 3 (30%)
  1. n: number of patients, BSC: best supportive care, *: p < 0.05 curative treatment vs BSC,
  2. **: p < 0.05 palliative treatment vs BSC, PDT: Phototherapy dynamic,
  3. : Many patients were not evaluable because they had died within 2 months